-
Posted by
Two Blokes Jun 12 -
Filed in
Stock
-
7 views
Imaging Biometrics Ltd (LSE:IBAI, OTCQB:IQAIF), a specialist in imaging-based therapies for brain cancers, said it will revise its application for Breakthrough Therapy Designation in the US, following discussions with the Food and Drug Administration. The company is developing oral gallium maltolate, a treatment aimed at aggressive brain tumours that have not responded to standard therapies.
